Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs

In recent years, the Federal Circuit has, with varying levels of agreement, considered what behavior by generic drugmakers constitutes inducement of infringement regarding so-called “off-label” prescribing for indications not covered in their approved label (known as a “skinnylabel; see “GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2020)“). In the latest instance...... By: McDonnell Boehnen Hulbert & Berghoff LLP